2017 Press Releases Keyword Search Year: 20202019201820172016201520142013 Jan 12, 2020 Summary ToggleAgios Announces “Agios 2025” Strategic Vision and Highlights 2020 Milestones Dec 23, 2019 Summary ToggleAgios to Present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 Dec 16, 2019 Summary ToggleAgios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) for the Treatment of Adult Patients with Relapsed or Refractory Myelodysplastic Syndrome with an IDH1 Mutation Dec 9, 2019 Summary ToggleAgios Presents Updated Data for Mitapivat from Extension Phase of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency Dec 9, 2019 Summary ToggleAgios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML) Dec 8, 2019 Summary ToggleAgios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results Dec 2, 2019 Summary ToggleAgios Appoints Bruce Car, Ph.D., as Chief Scientific Officer Nov 25, 2019 Summary ToggleAgios Appoints Jonathan Biller as Chief Legal Officer Nov 22, 2019 Summary ToggleAgios Presents New Pharmacodynamic and Response Data from Both Cohorts of the Perioperative Study of Vorasidenib and TIBSOVO® (ivosidenib) in Patients with IDH1 Mutant Positive Low-Grade Glioma Nov 13, 2019 Summary ToggleAgios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares Nov 7, 2019 Summary ToggleAgios Announces Pricing of $256 Million Public Offering of Common Stock Nov 6, 2019 Summary ToggleAgios Announces Proposed Offering of Common Stock Nov 6, 2019 Summary ToggleAgios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the 2019 ASH Annual Meeting Oct 31, 2019 Summary ToggleAgios Reports Business Highlights and Third Quarter 2019 Financial Results Oct 27, 2019 Summary ToggleAgios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTAP-Deleted Tumors Oct 17, 2019 Summary ToggleAgios to Webcast Conference Call of Third Quarter 2019 Financial Results on October 31, 2019 Oct 9, 2019 Summary ToggleAgios to Present Data from AG-270 Phase 1 Dose-Escalation Study in Patients with MTAP-Deleted Tumors in a Proffered Papers Oral Presentation and Poster Session at the AACR-NCI-EORTC International Conference Sep 30, 2019 Summary ToggleData from Agios’ Phase 3 ClarIDHy Trial of TIBSOVO® Demonstrates Significant Improvement in Progression Free Survival (PFS) Compared to Placebo in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients Sep 10, 2019 Summary ToggleAgios to Present Data From the Phase 3 ClarIDHy Study of TIBSOVO® in Previously Treated IDH1 Mutant Cholangiocarcinoma in Presidential Symposium at ESMO Sep 4, 2019 Summary ToggleAgios Announces Publication of Data for Mitapivat from Core and Extension Phases of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency in the New England Journal of Medicine Aug 29, 2019 Summary ToggleAgios to Present at the Citi 14th Annual Biotech Conference on Thursday, September 5, 2019 Aug 1, 2019 Summary ToggleAgios Reports Business Highlights and Second Quarter 2019 Financial Results Jul 18, 2019 Summary ToggleAgios to Webcast Conference Call of Second Quarter 2019 Financial Results on August 1, 2019 Jul 1, 2019 Summary ToggleAgios Announces Orlando Oliveira Appointed as Senior Vice President and General Manager, International Jun 10, 2019 Summary ToggleAgios to Present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2019 Jun 5, 2019 Summary ToggleAgios Announces the Planned Retirement of Chief Scientific Officer, Scott Biller, Ph.D., Effective December 31, 2019 Jun 3, 2019 Summary ToggleAgios Presents Updated Data from Phase 1 Studies of TIBSOVO® (ivosidenib) in Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy May 15, 2019 Summary ToggleAgios to Present Clinical Data from its IDH Program at ASCO May 15, 2019 Summary ToggleAgios Announces the Randomized Phase 3 ClarIDHy Trial of TIBSOVO® (ivosidenib) Achieved its Primary Endpoint in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients May 2, 2019 Summary ToggleAgios Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIBSOVO® as Monotherapy for Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy May 2, 2019 Summary ToggleAgios Reports Business Highlights and First Quarter 2019 Financial Results Apr 25, 2019 Summary ToggleAgios to Webcast Conference Call of First Quarter 2019 Financial Results on May 2, 2019 Apr 2, 2019 Summary ToggleAgios Announces New Commercial Leadership Structure Mar 26, 2019 Summary ToggleAgios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) with an IDH1 Mutation in Adult Patients Ineligible for Intensive Chemotherapy Mar 4, 2019 Summary ToggleAgios to Present at the Cowen 39th Annual Health Care Conference on Monday, March 11, 2019 Feb 25, 2019 Summary ToggleAgios Reports Updated Data from Phase 1 Study of Ivosidenib in Combination with Azacitidine Demonstrating Deep and Durable Responses in Newly Diagnosed IDH1 Mutant Acute Myeloid Leukemia (AML) Patients Feb 21, 2019 Summary ToggleAgios to Present at the Leerink Global Healthcare Conference on Thursday, February 28, 2019 Feb 20, 2019 Summary ToggleAgios Announces FDA Acceptance of Supplemental New Drug Application for TIBSOVO® (ivosidenib) for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation Not Eligible for Standard Therapy Feb 14, 2019 Summary ToggleAgios Reports Fourth Quarter and Full Year 2018 Financial Results Jan 31, 2019 Summary ToggleAgios to Webcast Conference Call of Fourth Quarter and Full Year 2018 Financial Results on February 14, 2019 Jan 7, 2019 Summary ToggleAgios Highlights Key 2019 Initiatives to Broaden Potential for Cancer and Rare Genetic Disease Programs to Build Long-Term Value Dec 28, 2018 Summary ToggleAgios to Present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 Dec 3, 2018 Summary ToggleAgios Presents Updated Data from the Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1 Mutant Positive Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible for Standard Treatment and Myelodysplastic Syndrome (MDS) Dec 3, 2018 Summary ToggleAgios Announces Updated Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Standard Induction and Consolidation Chemotherapy in Newly Diagnosed AML Patients With an IDH Mutation Nov 16, 2018 Summary ToggleAgios Presents Updated Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last